CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Report for D011001: Pleuropneumonia NIH

(Synonyms: Pleurop, Pleuropneumonia)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2859 iota carrageenan Wiki 1.00
drug1270 Ivermectin Wiki 0.24

Correlated MeSH Terms (0)

Name (Synonyms) Correlation

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel

Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease. It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases. Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.

NCT04425850 Contagious Pleuropneumonia Device: iota carrageenan Drug: Ivermectin
MeSH:Pleuropneumonia, Contagious Pleuropneumonia

Primary Outcomes

Description: For Health Personnel, the average dessertion all over the world has raised to 27 % worldwide. We aim at reducing it dramaticaly.

Measure: Reduction in contagion

Time: 30 days

Secondary Outcomes

Description: Allergy to any of the two drugs administered topically

Measure: Secondary and or side effects

Time: 7 days

HPO Nodes